ProKidney Corp.

As of June 30, 2026, ProKidney Corp. Class A carries a market capitalization of 7.51B, placing it among publicly traded companies globally. Its enterprise value stands at 23.73B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

ProKidney Corp. Class A's next confirmed earnings release is scheduled for November 16, 2026.

As of June 30, 2026, ProKidney Corp. Class A has 205.72M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 385.59, and the price-to-book ratio stands at -0.49.

These figures are as of June 30, 2026. The EV/Sales ratio of 1,660.26 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 23.73B versus a market cap of 7.51B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, ProKidney Corp. Class A maintains a current ratio of 8.36, meaning it holds 8.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 1.58, indicating elevated leverage, while an interest coverage ratio of -8,966.84 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended June 30, 2026. Return on assets (ROA) is negative at -27.10, reflecting losses generated across the asset base. The company generates approximately 63,731.41 in revenue per employee across its workforce of 224.25, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, ProKidney Corp. Class A recorded an income tax benefit of -17.91M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -2.91B and -1.47B in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, ProKidney Corp. Class A's stock has declined approximately 50.05% over the past 52 weeks. The 50-day moving average sits at 29.18, while the 200-day moving average is 38.70.

Over the twelve months ended June 30, 2026, ProKidney Corp. Class A generated 14.29M in revenue and converted that into -1.47B in net income, yielding earnings per share of -19.18. EBITDA reached -2.98B, while operating income came in at -3.10B.

As of June 30, 2026, ProKidney Corp. Class A holds 3.17B in cash and equivalents against 61.55M in total debt, resulting in a net debt position of -1.31B. Total book value stands at -15.44B, with working capital of 2.92B providing operational flexibility.

ProKidney Corp. Class A produced -2.47B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -324.40M in capital expenditures, free cash flow totaled -2.79B - equivalent to -18.48 per share.

These figures cover the twelve months ended June 30, 2026. The operating margin of -21,664.55 and net profit margin of -10,288.39 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -50.64: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -6.13, meaning ProKidney Corp. Class A raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, ProKidney Corp. Class A has an Altman Z-Score of 0.90, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.